CURI vs MGNI

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 29, 2026

CURI

47.9
AI Score
VS
MGNI Wins

MGNI

64.1
AI Score

Investment Advisor Scores

CURI

48score
Recommendation
HOLD

MGNI

64score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CURI MGNI Winner
Revenue 38.41M 357.19M MGNI
Net Income 7.55M 23.78M MGNI
Net Margin 19.7% 6.7% CURI
Operating Income 7.64M 38.94M MGNI
ROE 18.2% 2.5% CURI
ROA 11.2% 0.8% CURI
Total Assets 67.47M 3.03B MGNI
Cash 5.38M 332.62M MGNI
Current Ratio 0.78 1.03 MGNI

Relative Price Performance (Last 90 Days)

CURI 1M: -13.9% · 3M: -13.9% MGNI 1M: +13.7% · 3M: +17.2%

Current Technical Phase

CURI

Markdown
Sell / avoid

Price below a falling SMA50 (slope -3.0%), weak momentum, RSI 35

RSI (14): 35.2 · Price: $2.41

MGNI

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 70

RSI (14): 69.8 · Price: $28.52

Fundamentals Snapshot

Metric CURI MGNI
Market Cap — —
Forward P/E 7.8 21.1
Trailing P/E — 24.2
Revenue (TTM) — —
Revenue Growth 0.2% 0.1%
Gross Margin 0.6% 0.7%
Operating Margin 0.4% 0.2%
EPS 0.00 1.20
Dividend Yield 0.13% —

Frequently Asked Questions

Based on our detailed analysis, MGNI is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.